The current strategy for managing chronic gout is the use of uric-acid-lowering drugs to reduce urate production or of a uricosuric agent to promote renal uric acid excretion. Probenecid is ...

It’s a common ailment for those with lavish tastes—and for the convivial. But it really can strike anyone. But good news for ...

Summary. Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase for the management of hyperuricemia in patients with gout. The ability of febuxostat to decrease serum uric acid ...

Untreated gout places a substantial burden on the global health system, as chronic gout causes tophi formation, chronic joint ...

Most of the glomeruli were involved in dense scarring with surrounding chronic inflammatory ... There was a history of gout for many years. Tophi were present on the joints of both hands and ...

Severe gout was defined by the presence of 5 or more tophi. The mechanisms of generalized neuropathy remain unclear and likely involve multiple factors. Patients with gout and neuropathic symptoms ...

crystals form and collect in your joints and cause gout. Uric acid buildup also can lead to disfiguring lumps called tophi that form around the affected joint. And if the crystals accumulate in ...

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to ...

This highlights the FDA's recognition of the serious and disabling nature of gout in patients with clinically visible tophi and the potential ... painful flare-ups and chronic symptoms.

Gout affects around 9 million Americans, and around 50% of those with gout will have their first attacks begin in the big toe. The severity of gout will depend on the individual, but, on average ...